Literature DB >> 29381045

Mechanism Underlying the Effectiveness of Deferiprone in Alleviating Parkinson's Disease Symptoms.

Yingying Sun1, An Ninh Pham1, T David Waite1.   

Abstract

Elevation in iron content as well as severe depletion of dopamine (DA) as a result of iron-induced loss of dopaminergic neurons has been recognized to accompany the progression of Parkinson's disease (PD). To better understand the mechanism of the mitigating effect of the iron chelator deferiprone (DFP) on PD, the interplay between iron and DFP was investigated both in the absence and presence of DA. The results show that DFP was extremely efficient in scavenging both aqueous iron and iron that was loosely bound to DA with the entrapment of iron in Fe-DFP complexed form critical to halting the iron catalyzed degradation of DA and associated generation of toxic metabolites. The DFP related scavenging of dopamine semiquinone (DA•-) and superoxide (O2•-) may also contribute to its positive effects in the treatment of PD.

Entities:  

Keywords:  Deferiprone; Parkinson’s disease; dopamine; iron overload; mechanism; oxidative stress

Mesh:

Substances:

Year:  2018        PMID: 29381045     DOI: 10.1021/acschemneuro.7b00478

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  5 in total

1.  Design and synthesis of N-hydroxyalkyl substituted deferiprone: a kind of iron chelating agents for Parkinson's disease chelation therapy strategy.

Authors:  Qingchun Zhang; Shufan Feng; Yulian Zhao; Bo Jin; Rufang Peng
Journal:  J Biol Inorg Chem       Date:  2021-05-08       Impact factor: 3.358

Review 2.  Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders.

Authors:  Dharmendra Kumar Khatri; Amey Kadbhane; Monica Patel; Shweta Nene; Srividya Atmakuri; Saurabh Srivastava; Shashi Bala Singh
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-04-08

3.  Kinetic Modeling of pH-Dependent Oxidation of Dopamine by Iron and Its Relevance to Parkinson's Disease.

Authors:  Yingying Sun; A Ninh Pham; Dominic J Hare; T David Waite
Journal:  Front Neurosci       Date:  2018-11-26       Impact factor: 4.677

Review 4.  Genotype-driven therapeutic developments in Parkinson's disease.

Authors:  Jannik Prasuhn; Norbert Brüggemann
Journal:  Mol Med       Date:  2021-04-19       Impact factor: 6.354

5.  Aging is associated with increased brain iron through cortex-derived hepcidin expression.

Authors:  Tatsuya Sato; Jason Solomon Shapiro; Hsiang-Chun Chang; Richard A Miller; Hossein Ardehali
Journal:  Elife       Date:  2022-01-11       Impact factor: 8.140

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.